Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | F2 | P00734 | 1/20 | 0.40 |
| ▸ | PLAU | P00749 | 1/20 | 0.40 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.40 |
| ▸ | ELANE | P08246 | 1/20 | 0.40 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 3/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25337 | 0.81 | MAPT (0.43) | ALDH1A1KMT2AMAPTKDM4ERAB9A | |
| SCHEMBL25753536 | 0.74 | TDP1 (0.51) | ALDH1A1KMT2AMAPTKDM4EELANE | |
| SCHEMBL19492477 | 0.73 | TDP1 (0.47) | ALDH1A1KMT2AMAPTKDM4ELMNA | |
| SCHEMBL5813872 | 0.71 | PDE4A (0.41) | ALDH1A1KMT2AMAPTKDM4EF2 | |
| SCHEMBL610407 | 0.70 | SMN1; SMN2 (0.39) | ALDH1A1KMT2AMAPTKDM4EF2 | |
| SCHEMBL24423706 | 0.69 | ALDH1A1 (0.47) | ALDH1A1KMT2AMAPTKDM4ERAB9A | |
| SCHEMBL11712185 | 0.69 | KMT2A (0.52) | ALDH1A1KMT2AGAALMNAMEN1 | |
| SCHEMBL27415197 | 0.69 | SMN1; SMN2 (0.55) | ALDH1A1KMT2AMAPTRAB9AMEN1 | |
| SCHEMBL22826520 | 0.69 | ALDH1A1 (0.44) | ALDH1A1KMT2AMAPTGAARAB9A | |
| SCHEMBL28416025 | 0.69 | MDM2 (0.46) | ALDH1A1KMT2ACTRB1RAB9AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7919496-B2 | 5-[4-(2-Trifluoromethylbenzoyl)piperazin-1-yl]-[1,3,4]thiadiazole-2-carboxylic acid ethyl ester; metabolic disorders type II diabetes, impaired glucose tolerance, insulin resistance, obesity, fatty liver, non-alcoholic steatohepatitis, dyslipidemia and metabolic syndrome; cardiovascular disorders | XENON PHARMACEUTICALS INC. (CA) | 2011-04-05 | — | — | US | disclosed |
| EP-2289510-A1 | Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-coa desaturase enzymes | Xenon Pharmaceuticals Inc. (CA) | 2011-03-02 | — | — | EP | disclosed |
| US-20080108629-A1 | Heterocyclic Derivatives for the Treatment of Diseases Mediated by Stearoyl-Coa Desaturase Enzymes | XENON PHARMACEUTICALS INC. (CA) | 2008-05-08 | — | — | US | disclosed |
| CN-101083982-A | Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-coa desaturase enzymes | XENON PHARMACEUTICALS INC (CA) | 2007-12-05 | — | — | CN | disclosed |
| EP-1830837-A2 | HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY STEAROYL-COA DESATURASE ENZYMES | XENON PHARMACEUTICALS INC. (CA) | 2007-09-12 | — | — | EP | disclosed |
| WO-2006034315-A2 | HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY STEAROYL-COA DESATURASE ENZYMES | XENON PHARMACEUTICALS INC. (CA) | 2006-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080108629-A1 | Heterocyclic Derivatives for the Treatment of Diseases Mediated by Stearoyl-Coa Desaturase Enzymes | SCD, SCD5, ECHS1 | ALDH1A1 1346/4885KMT2A 989/4885MAPT 4243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.